Siglec-1 (
sialoadhesin, CD169) is a surface receptor on human cells that mediates trans-enhancement of HIV-1
infection through recognition of
sialic acid moieties in virus membrane
gangliosides. Here, we demonstrate that mouse
Siglec-1, expressed on the surface of primary macrophages in an
interferon-α-responsive manner, captures murine leukemia virus (MLV) particles and mediates their transfer to proliferating lymphocytes. The MLV
infection of primary B-cells was markedly more efficient than that of primary T-cells. The major structural
protein of MLV particles, Gag, frequently co-localized with
Siglec-1, and trans-
infection, primarily of surface-bound MLV particles, efficiently occurred. To explore the role of
sialic acid for MLV trans-
infection at a submolecular level, we analyzed the potential of six
sialic acid precursor analogs to modulate the sialylated
ganglioside-dependent interaction of MLV particles with
Siglec-1. Biosynthetically engineered
sialic acids were detected in both the
glycolipid and
glycoprotein fractions of MLV producer cells. MLV released from cells carrying N-acyl-modified
sialic acids displayed strikingly different capacities for Siglec-1-mediated capture and trans-
infection; N-butanoyl, N-isobutanoyl, N-glycolyl, or N-pentanoyl side chain modifications resulted in up to 92 and 80% reduction of virus particle capture and trans-
infection, respectively, whereas N-propanoyl or N-cyclopropylcarbamyl side chains had no effect. In agreement with these functional analyses, molecular modeling indicated reduced binding affinities for non-functional N-acyl modifications. Thus,
Siglec-1 is a key receptor for macrophage/lymphocyte trans-
infection of surface-bound virions, and the N-acyl side chain of
sialic acid is a critical determinant for the
Siglec-1/MLV interaction.